EPHA5, His, Cynomolgus
EPHA5, His, Cynomolgus

The purity of EPHA5, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

EPHA5, His, Cynomolgus

EPHA5, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

EPHA5, His, Cynomolgus

Ephrin type-A receptor 5 (EphA5) expression was detected in all non-tumor gastric epithelia but was differentially expressed among gastric cancer samples. EphA5 is differentially expressed in gastric cancer. EphA5 may therefore be a potential therapeutic target and may have clinical utility as a marker for lymph node metastasis in gastric cancer.
Z04784
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
EPHA5 (Pro25-Gln572)
Accession # A0A2K5W6J6		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 61.73 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-75kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • EPHA5, His, Cynomolgus
    • EPHA5, His, Cynomolgus

    The purity of EPHA5, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • EPHA5, His, Cynomolgus
    • EPHA5, His, Cynomolgus

    EPHA5, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Ephrin type-A receptor 5 (EphA5) expression was detected in all non-tumor gastric epithelia but was differentially expressed among gastric cancer samples. EphA5 is differentially expressed in gastric cancer. EphA5 may therefore be a potential therapeutic target and may have clinical utility as a marker for lymph node metastasis in gastric cancer.
Synonyms EHK-1; EK7; BSK; EHK1; HEK7; TYRO4; EphA5; Rek7; TYRO4HEK7CEK7

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.